398 related articles for article (PubMed ID: 36157483)
1. Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.
Kandettu A; Adiga D; Devi V; Suresh PS; Chakrabarty S; Radhakrishnan R; Kabekkodu SP
Genes Dis; 2022 Nov; 9(6):1443-1465. PubMed ID: 36157483
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of miRNA clusters in breast cancer progression.
Kandettu A; Radhakrishnan R; Chakrabarty S; Sriharikrishnaa S; Kabekkodu SP
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188413. PubMed ID: 32827583
[TBL] [Abstract][Full Text] [Related]
3. Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.
Mandilaras V; Vernon M; Meryet-Figuière M; Karakasis K; Lambert B; Poulain L; Oza A; Denoyelle C; Lheureux S
Expert Opin Biol Ther; 2017 Aug; 17(8):927-943. PubMed ID: 28641048
[TBL] [Abstract][Full Text] [Related]
4. Network analysis of microRNAs and their regulation in human ovarian cancer.
Schmeier S; Schaefer U; Essack M; Bajic VB
BMC Syst Biol; 2011 Nov; 5():183. PubMed ID: 22050994
[TBL] [Abstract][Full Text] [Related]
5. Clustered miRNAs and their role in biological functions and diseases.
Kabekkodu SP; Shukla V; Varghese VK; D' Souza J; Chakrabarty S; Satyamoorthy K
Biol Rev Camb Philos Soc; 2018 Nov; 93(4):1955-1986. PubMed ID: 29797774
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.
Xue B; Li S; Jin X; Liu L
BMC Cancer; 2021 Apr; 21(1):452. PubMed ID: 33892654
[TBL] [Abstract][Full Text] [Related]
7. miRNA and cancer; computational and experimental approaches.
Tutar Y
Curr Pharm Biotechnol; 2014; 15(5):429. PubMed ID: 25189575
[TBL] [Abstract][Full Text] [Related]
8. Genomic analysis of rice microRNA promoters and clusters.
Cui X; Xu SM; Mu DS; Yang ZM
Gene; 2009 Feb; 431(1-2):61-6. PubMed ID: 19073239
[TBL] [Abstract][Full Text] [Related]
9. Cluster miRNAs and cancer: Diagnostic, prognostic and therapeutic opportunities.
Kabekkodu SP; Shukla V; Varghese VK; Adiga D; Vethil Jishnu P; Chakrabarty S; Satyamoorthy K
Wiley Interdiscip Rev RNA; 2020 Mar; 11(2):e1563. PubMed ID: 31436881
[TBL] [Abstract][Full Text] [Related]
10. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
Mahdian-Shakib A; Dorostkar R; Tat M; Hashemzadeh MS; Saidi N
Biomed Pharmacother; 2016 Dec; 84():592-600. PubMed ID: 27694003
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study.
Krasniqi E; Sacconi A; Marinelli D; Pizzuti L; Mazzotta M; Sergi D; Capomolla E; Donzelli S; Carosi M; Bagnato A; Gamucci T; Tomao S; Natoli C; Marchetti P; Grassadonia A; Tinari N; De Tursi M; Vizza E; Ciliberto G; Landi L; Cappuzzo F; Barba M; Blandino G; Vici P
Biomark Res; 2021 Jul; 9(1):57. PubMed ID: 34256855
[TBL] [Abstract][Full Text] [Related]
12. ChrXq27.3 miRNA cluster functions in cancer development.
Yoshida K; Yokoi A; Yamamoto Y; Kajiyama H
J Exp Clin Cancer Res; 2021 Mar; 40(1):112. PubMed ID: 33766100
[TBL] [Abstract][Full Text] [Related]
13. miRNAs and ovarian cancer: An overview.
Deb B; Uddin A; Chakraborty S
J Cell Physiol; 2018 May; 233(5):3846-3854. PubMed ID: 28703277
[TBL] [Abstract][Full Text] [Related]
14. Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer.
Berkel C; Cacan E
Hum Cell; 2021 May; 34(3):862-877. PubMed ID: 33576947
[TBL] [Abstract][Full Text] [Related]
15. Comparative Analysis of Differentially Expressed miRNAs and their Downstream mRNAs in Ovarian Cancer and its Associated Endometriosis.
Wu RL; Ali S; Bandyopadhyay S; Alosh B; Hayek K; Daaboul MF; Winer I; Sarkar FH; Ali-Fehmi R
J Cancer Sci Ther; 2015; 7(7):258-265. PubMed ID: 26819681
[TBL] [Abstract][Full Text] [Related]
16. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.
Vescarelli E; Gerini G; Megiorni F; Anastasiadou E; Pontecorvi P; Solito L; De Vitis C; Camero S; Marchetti C; Mancini R; Benedetti Panici P; Dominici C; Romano F; Angeloni A; Marchese C; Ceccarelli S
J Exp Clin Cancer Res; 2020 Jan; 39(1):3. PubMed ID: 31898520
[TBL] [Abstract][Full Text] [Related]
17. Expression and clinical significance of lncRNA BC041954 in ovarian cancer.
Lu YM; Guo YR; Zhou MY; Wang Y
Exp Ther Med; 2022 Jun; 23(6):408. PubMed ID: 35619633
[TBL] [Abstract][Full Text] [Related]
18. Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape.
Zou X; Zhao Y; Liang X; Wang H; Zhu Y; Shao Q
Front Immunol; 2021; 12():641937. PubMed ID: 33868274
[TBL] [Abstract][Full Text] [Related]
19. miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma.
Tuncer SB; Erdogan OS; Erciyas SK; Saral MA; Celik B; Odemis DA; Turkcan GK; Yazici H
J Ovarian Res; 2020 Aug; 13(1):99. PubMed ID: 32854743
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells.
Moghbeli M
J Ovarian Res; 2021 Sep; 14(1):127. PubMed ID: 34593006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
